A phase 1 double-blind, randomized, two-arm, two-way crossover, sequential two-stage study to assess the pharmacokinetic comparability of first and second generation RO7490677 (recombinant human pentraxin-2; rhPTX-2) drug products in healthy subjects
Latest Information Update: 13 Apr 2023
At a glance
- Drugs Zinpentraxin alfa (Primary)
- Indications Idiopathic pulmonary fibrosis; Myelofibrosis; Non-alcoholic steatohepatitis; Scars
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Roche
Most Recent Events
- 13 Apr 2023 Status changed from active, no longer recruiting to completed.
- 02 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 04 Jul 2022 Status changed from not yet recruiting to recruiting.